Citations (163)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Robert A. Copeland. (2021) Evolution of the drug-target residence time model. Expert Opinion on Drug Discovery 16:12, pages 1441-1451.
Read now
Read now
Rumin Zhang & Kenny Wong. (2017) High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery. Expert Opinion on Drug Discovery 12:1, pages 17-37.
Read now
Read now
Vadim Bernard-Gauthier & Ralf Schirrmacher. (2016) Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition. Expert Opinion on Therapeutic Patents 26:2, pages 291-295.
Read now
Read now
Wilhelmus EA de Witte, Yin Cheong Wong, Indira Nederpelt, Laura H Heitman, Meindert Danhof, Piet H van der Graaf, Ron AHJ Gilissen & Elizabeth C.M. de Lange. (2016) Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Expert Opinion on Drug Discovery 11:1, pages 45-63.
Read now
Read now
Georges Vauquelin. (2015) On the ‘micro’-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action. Expert Opinion on Drug Discovery 10:10, pages 1085-1098.
Read now
Read now
Rumin Zhang & Michael Kavana. (2015) Quantitative analysis of receptor allosterism and its implication for drug discovery. Expert Opinion on Drug Discovery 10:7, pages 763-780.
Read now
Read now
Karim M ElSawy, Adelene Sim, David P Lane, Chandra S Verma & Leo SD Caves. (2015) A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2. Cell Cycle 14:2, pages 179-188.
Read now
Read now
Karim ElSawy, Chandra S. Verma, David P. Lane & Leo Caves. (2013) On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein. Cell Cycle 12:24, pages 3727-3735.
Read now
Read now
Karim ElSawy, Chandra S. Verma, Thomas Leonard Joseph, David P. Lane, Reidun Twarock & Leo Caves. (2013) On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study. Cell Cycle 12:3, pages 394-404.
Read now
Read now
Ye Fang. (2012) Ligand–receptor interaction platforms and their applications for drug discovery. Expert Opinion on Drug Discovery 7:10, pages 969-988.
Read now
Read now
Georges Vauquelin & Isabelle Van Liefde. (2012) Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems. Expert Opinion on Drug Discovery 7:7, pages 583-595.
Read now
Read now
Kun Bi, Connie S Lebakken & Kurt W Vogel. (2011) Transformation of in vitro tools for kinase profiling: keeping an eye over the off-target liabilities. Expert Opinion on Drug Discovery 6:7, pages 701-712.
Read now
Read now
Rumin Zhang & Frederick Monsma. (2010) Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs. Expert Opinion on Drug Discovery 5:11, pages 1023-1029.
Read now
Read now
Georges Vauquelin. (2010) Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opinion on Drug Discovery 5:10, pages 927-941.
Read now
Read now
Articles from other publishers (149)
Ryo Matsunaga, Kan Ujiie, Mayuko Inagaki, Jorge Fernández Pérez, Yoshiki Yasuda, Shinya Mimasu, Shinji Soga & Kouhei Tsumoto. (2023) High-throughput analysis system of interaction kinetics for data-driven antibody design. Scientific Reports 13:1.
Crossref
Crossref
Anirban Mukherjee, Farzad Zamani & Takayoshi Suzuki. (2023) Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms. Journal of Medicinal Chemistry 66:17, pages 11672-11700.
Crossref
Crossref
R. Özçelik, D. van Tilborg, J. Jiménez‐Luna & F. Grisoni. (2023) Structure‐Based Drug Discovery with Deep Learning**. ChemBioChem 24:13.
Crossref
Crossref
Francesco Di Palma, Carlo Abate, Sergio Decherchi & Andrea Cavalli. (2023) Ligandability and druggability assessment via machine learning. WIREs Computational Molecular Science.
Crossref
Crossref
Bharath Srinivasan. (2022) A guide to enzyme kinetics in early drug discovery. The FEBS Journal 290:9, pages 2292-2305.
Crossref
Crossref
Robert A. Copeland. 2023. Enzymes. Enzymes
83
124
.
Georges Vauquelin & Dominique Maes. (2022) Competition in drug binding and … the race to equilibrium. Fundamental & Clinical Pharmacology 37:1, pages 147-157.
Crossref
Crossref
Chayna Sarkar, Biswadeep Das, Vikram Singh Rawat, Julie Birdie Wahlang, Arvind Nongpiur, Iadarilang Tiewsoh, Nari M. Lyngdoh, Debasmita Das, Manjunath Bidarolli & Hannah Theresa Sony. (2023) Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. International Journal of Molecular Sciences 24:3, pages 2026.
Crossref
Crossref
Jessica Goss, Pamela Hair, Parvathi Kumar, Giuseppina Iacono, Laura Redden, Gaetano Morelli, Neel Krishna, Ulrich Thienel & Kenji Cunnion. (2023) RLS-0071, a dual-targeting anti-inflammatory peptide - biomarker findings from a first in human clinical trial. Translational Medicine Communications 8:1.
Crossref
Crossref
Bharath Srinivasan. 2023. Modern Methods of Drug Design and Development. Modern Methods of Drug Design and Development
85
108
.
Xinfeng Zhao, Qian Li, Jing Wang, Qi Liang & Jia QuanXinfeng Zhao, Qian Li, Jing Wang, Qi Liang & Jia Quan. 2023. G Protein-Coupled Receptors. G Protein-Coupled Receptors
65
69
.
Sonia Ziada, Julien Diharce, Eric Raimbaud, Samia Aci-Sèche, Pierre Ducrot & Pascal Bonnet. (2022) Estimation of Drug-Target Residence Time by Targeted Molecular Dynamics Simulations. Journal of Chemical Information and Modeling 62:22, pages 5536-5549.
Crossref
Crossref
Pierre Sabatier, Christian M. Beusch, Zhaowei Meng & Roman A. Zubarev. (2022) System-Wide Profiling by Proteome Integral Solubility Alteration Assay of Drug Residence Times for Target Characterization. Analytical Chemistry 94:45, pages 15772-15780.
Crossref
Crossref
Naresh Balachandran, Ryan A. Grainger, Tamanna Rob, Peter Liuni, Derek J. Wilson, Murray S. Junop & Paul J. Berti. (2022) Role of Half-of-Sites Reactivity and Inter-Subunit Communications in DAHP Synthase Catalysis and Regulation. Biochemistry 61:20, pages 2229-2240.
Crossref
Crossref
Karim M. ElSawy, Fahad M. Alminderej & Leo S. D. Caves. (2022) Design of peptide-based coronavirus inhibitors that target disruption of 3CLpro protease self-association. Molecular Systems Design & Engineering 7:9, pages 1138-1153.
Crossref
Crossref
Bo Yao, Yunze Yang, Nanxi Yu, Nongjian Tao, Di Wang, Shaopeng Wang & Fenni Zhang. (2022) Label‐Free Quantification of Molecular Interaction in Live Red Blood Cells by Tracking Nanometer Scale Membrane Fluctuations. Small 18:28.
Crossref
Crossref
Arvind Negi & Anne Sophie Voisin‐Chiret. (2022)
Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x
L
Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
. ChemBioChem 23:12.
Crossref
Crossref
Elma Mons, Sander Roet, Robbert Q. Kim & Monique P. C. Mulder. (2022) A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations. Current Protocols 2:6.
Crossref
Crossref
Ealin N. Patel, Lewis D. Turner, Mark S. Hixon & Kim D. Janda. (2022) Identification of Slow-Binding Inhibitors of the BoNT/A Protease. ACS Medicinal Chemistry Letters 13:4, pages 742-747.
Crossref
Crossref
Suresh Dara, Swetha Dhamercherla, Surender Singh Jadav, CH Madhu Babu & Mohamed Jawed Ahsan. (2021) Machine Learning in Drug Discovery: A Review. Artificial Intelligence Review 55:3, pages 1947-1999.
Crossref
Crossref
Charles S. Lay, Daniel A. Thomas, John P. Evans, Matthew Campbell, Kristopher McCombe, Alexander N. Phillipou, Laurie J. Gordon, Emma J. Jones, Kristin Riching, Mahnoor Mahmood, Cassie Messenger, Charlotte E. Carver, Kelly M. Gatfield & Peter D. Craggs. (2022) Development of an intracellular quantitative assay to measure compound binding kinetics. Cell Chemical Biology 29:2, pages 287-299.e8.
Crossref
Crossref
Wen-Ting Chu, Zhiqiang Yan, Xiakun Chu, Xiliang Zheng, Zuojia Liu, Li Xu, Kun Zhang & Jin Wang. (2021) Physics of biomolecular recognition and conformational dynamics. Reports on Progress in Physics 84:12, pages 126601.
Crossref
Crossref
Zhengli Bai, Menglong Xu, Ying Mei, Tuo Hu, Panpan Zhang, Manman Chen, Wenxiu Lv, Chenchen Lu & Shuhua Tan. (2021) Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines 9:12, pages 1783.
Crossref
Crossref
Seiji Kawashita, Koichi Aoyagi, Kyoko Fukushima, Rie Hantani, Shiori Naruoka, Atsuo Tanimoto, Yuji Hori, Yukiyo Toyonaga, Hiroshi Yamanaka, Susumu Miyazaki & Yoshiji Hantani. (2021) SAR study of small molecule inhibitors of the programmed cell death‐1/programmed cell death‐ligand 1 interaction. Chemical Biology & Drug Design 98:5, pages 914-929.
Crossref
Crossref
Georges Vauquelin & Dominique Maes. (2021) Induced fit versus conformational selection: From rate constants to fluxes… and back to rate constants. Pharmacology Research & Perspectives 9:5.
Crossref
Crossref
Gaochao Tian, Javier Suarez, Zhuming Zhang, Pete Connolly & Kay Ahn. (2021) Potent Phenylpyridine and Oxodihydrofuran Inhibitors of Cyclooxygenase-2: Optimization toward a Long Residence Time with Balanced Internal Energetics. Biochemistry 60:31, pages 2407-2418.
Crossref
Crossref
Puneet Khurana, Lisa McWilliams, Jonathan Wingfield, Derek Barratt & Bharath Srinivasan. (2021) A Novel High-Throughput FLIPR Tetra–Based Method for Capturing Highly Confluent Kinetic Data for Structure–Kinetic Relationship Guided Early Drug Discovery. SLAS Discovery 26:5, pages 684-697.
Crossref
Crossref
Menglong Xu, Gaoxin Lei, Manman Chen, Ke Wang, Wenxiu Lv, Panpan Zhang, Tuo Hu, Jie Gao, Chenchen Lu, Ying Mei, Zhipan Xu, Zhengli Bai, Huajing Hu, Yiwei Jiang & Shuhua Tan. (2021) Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine 65, pages 103250.
Crossref
Crossref
Carl-Johan Carling & Mikael Brülls. (2021) Milling of poorly soluble crystalline drug compounds to generate appropriate particle sizes for inhaled sustained drug delivery. International Journal of Pharmaceutics 593, pages 120116.
Crossref
Crossref
Jianmin Gao & Vincent Nobile. 2021. The Design of Covalent-Based Inhibitors. The Design of Covalent-Based Inhibitors
75
94
.
Ernest Awoonor-Williams, Jacob Kennedy & Christopher N. Rowley. 2021. The Design of Covalent-Based Inhibitors. The Design of Covalent-Based Inhibitors
203
227
.
Azra Hamidović, Ena Hasković, Sumeja Muhić, Matej Planinić, Naida Omerović & Selma Škrbo. 2021. CMBEBIH 2021. CMBEBIH 2021
499
510
.
Georges Vauquelin, Dominique Maes & David C. Swinney. (2020) Fluxes for Unraveling Complex Binding Mechanisms. Trends in Pharmacological Sciences 41:12, pages 923-932.
Crossref
Crossref
Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Milen Todorov, Pierre Nimsgern, Sebastien Ripoche, Michel Niklaus, Nicolas Warin, Van Huy Luu, Mario Madoerin, Jasmin Wirth, Diana Graus-Porta, Andreas Weiss, Michael Kiffe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Dario Sterker, Christelle Stamm, Flavia Adler, Alexandra Buhles, Heiko Schadt, Philippe Couttet, Jutta Blank, Inga Galuba, Jörg Trappe, Johannes Voshol, Nils Ostermann, Chao Zou, Jörg Berghausen, Alberto Del Rio Espinola, Wolfgang Jahnke & Pascal Furet. (2020) Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. Journal of Medicinal Chemistry 63:21, pages 12542-12573.
Crossref
Crossref
Matthew D. Lloyd. (2020) High-Throughput Screening for the Discovery of Enzyme Inhibitors. Journal of Medicinal Chemistry 63:19, pages 10742-10772.
Crossref
Crossref
Sofya V. Lushchekina & Patrick Masson. (2020) Slow-binding inhibitors of acetylcholinesterase of medical interest. Neuropharmacology 177, pages 108236.
Crossref
Crossref
D. V. Borisov & A.V. Veselovsky. (2020) Ligand–Receptor Binding Kinetics in Drug Design. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry 14:3, pages 228-240.
Crossref
Crossref
Peter Florian, Klaus R. Flechsenhar, Eckart Bartnik, Danping Ding‐Pfennigdorff, Matthias Herrmann, Paul J. Bryce & Frank O. Nestle. (2019) Translational drug discovery and development with the use of tissue‐relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy. Experimental Dermatology 29:1, pages 4-14.
Crossref
Crossref
Bruno Rizzuti & Fedora Grande. 2020. Protein Homeostasis Diseases. Protein Homeostasis Diseases
309
327
.
Indrani Bera & Pavan V. Payghan. (2019) Use of Molecular Dynamics Simulations in Structure-Based Drug Discovery. Current Pharmaceutical Design 25:31, pages 3339-3349.
Crossref
Crossref
Vladimir Popović, Edward Morrison, Adam Z. Rosanally, Naresh Balachandran, Alexander W. Senson, Robert Szabla, Murray S. Junop & Paul J. Berti. (2019) NeuNAc Oxime: A Slow-Binding and Effectively Irreversible Inhibitor of the Sialic Acid Synthase NeuB. Biochemistry 58:41, pages 4236-4245.
Crossref
Crossref
Adriaan P. IJzerman & Dong Guo. (2019) Drug–Target Association Kinetics in Drug Discovery. Trends in Biochemical Sciences 44:10, pages 861-871.
Crossref
Crossref
Wang, Ji, Li, Wang, Gong, Wang, Liu & Pan. (2019) Utilizing the Combination of Binding Kinetics and Micro-Pharmacokinetics Link in Vitro α-Glucosidase Inhibition to in Vivo Target Occupancy. Biomolecules 9:9, pages 493.
Crossref
Crossref
Nazanin Donyapour, Nicole M. Roussey & Alex Dickson. (2019) REVO: Resampling of ensembles by variation optimization. The Journal of Chemical Physics 150:24.
Crossref
Crossref
Franz‐Josef Meyer‐Almes. (2018) Determination of the binding mechanism of histone deacetylase inhibitors. Chemical Biology & Drug Design 93:6, pages 1214-1250.
Crossref
Crossref
Behnoush Hajian, Eric Scocchera, Carolyn Shoen, Jolanta Krucinska, Kishore Viswanathan, Narendran G-Dayanandan, Heidi Erlandsen, Alexavier Estrada, Katarína Mikušová, Jana Korduláková, Michael Cynamon & Dennis Wright. (2019) Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents. Cell Chemical Biology 26:6, pages 781-791.e6.
Crossref
Crossref
Zhan Zhou, Xiaojuan Chen, Ying Fu, Ye Zhang, Shuyan Dai, Jun Li, Lin Chen, Guangyu Xu, Zhuchu Chen & Yongheng Chen. (2019) Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. Chemical Communications 55:42, pages 5890-5893.
Crossref
Crossref
Feisheng Zhong, Jing Xing, Xutong Li, Xiaohong Liu, Zunyun Fu, Zhaoping Xiong, Dong Lu, Xiaolong Wu, Jihui Zhao, Xiaoqin Tan, Fei Li, Xiaomin Luo, Zhaojun Li, Kaixian Chen, Mingyue Zheng & Hualiang Jiang. (2018) Artificial intelligence in drug design. Science China Life Sciences 61:10, pages 1191-1204.
Crossref
Crossref
Simanga R. Gama, Naresh Balachandran & Paul J. Berti. (2018)
Campylobacter jejuni
KDO8P Synthase, Its Inhibition by KDO8P Oxime, and Control of the Residence Time of Slow-Binding Inhibition
. Biochemistry 57:36, pages 5327-5338.
Crossref
Crossref
Pascal Zihlmann, Marleen Silbermann, Timothy Sharpe, Xiaohua Jiang, Tobias Mühlethaler, Roman P. Jakob, Said Rabbani, Christoph P. Sager, Priska Frei, Lijuan Pang, Timm Maier & Beat Ernst. (2018) KinITC—One Method Supports both Thermodynamic and Kinetic SARs as Exemplified on FimH Antagonists. Chemistry – A European Journal 24:49, pages 13049-13057.
Crossref
Crossref
Amiram Sananes, Itay Cohen, Anat Shahar, Alexandra Hockla, Elena De Vita, Aubry K. Miller, Evette S. Radisky & Niv Papo. (2018) A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. Journal of Biological Chemistry 293:33, pages 12663-12680.
Crossref
Crossref
Philip Hinchliffe, Carol A. Tanner, Anthony P. Krismanich, Geneviève Labbé, Valerie J. Goodfellow, Laura Marrone, Ahmed Y. Desoky, Karina Calvopiña, Emily E. WhittleFanxing Zeng, Matthew B. AvisonNiels C. Bols, Stefan Siemann, James Spencer & Gary I. Dmitrienko. (2018) Structural and Kinetic Studies of the Potent Inhibition of Metallo-β-lactamases by 6-Phosphonomethylpyridine-2-carboxylates. Biochemistry 57:12, pages 1880-1892.
Crossref
Crossref
Richard S. Roberts, Sara Sevilla, Manel Ferrer, Joan Taltavull, Begoña Hernández, Victor Segarra, Jordi Gràcia, Martin D. Lehner, Amadeu Gavaldà, Miriam Andrés, Judit Cabedo, Dolors Vilella, Peter Eichhorn, Elena Calama, Carla Carcasona & Montserrat Miralpeix. (2018)
4-Amino-7,8-dihydro-1,6-naphthyridin-5(6
H
)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships
. Journal of Medicinal Chemistry 61:6, pages 2472-2489.
Crossref
Crossref
Masato Yoshikawa, Morihisa Saitoh, Taisuke Katoh, Tomohiro Seki, Simone V. Bigi, Yuji Shimizu, Tsuyoshi Ishii, Takuro Okai, Masako Kuno, Harumi Hattori, Etsuro Watanabe, Kumar S. Saikatendu, Hua Zou, Masanori Nakakariya, Takayuki Tatamiya, Yoshihisa Nakada & Takatoshi Yogo. (2018)
Discovery of 7-Oxo-2,4,5,7-tetrahydro-6
H
-pyrazolo[3,4-
c
]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure–Kinetic Relationships
. Journal of Medicinal Chemistry 61:6, pages 2384-2409.
Crossref
Crossref
Justin M. Di Trani, Stephane De Cesco, Rebecca O’Leary, Jessica Plescia, Claudia Jorge do Nascimento, Nicolas Moitessier & Anthony K. Mittermaier. (2018) Rapid measurement of inhibitor binding kinetics by isothermal titration calorimetry. Nature Communications 9:1.
Crossref
Crossref
Tianao Yuan & Nicole S. Sampson. (2018) Hit Generation in TB Drug Discovery: From Genome to Granuloma. Chemical Reviews 118:4, pages 1887-1916.
Crossref
Crossref
Fenni Zhang, Wenwen Jing, Ashley Hunt, Hui Yu, Yunze Yang, Shaopeng Wang, Hong-Yuan Chen & Nongjian Tao. (2018) Label-Free Quantification of Small-Molecule Binding to Membrane Proteins on Single Cells by Tracking Nanometer-Scale Cellular Membrane Deformation. ACS Nano 12:2, pages 2056-2064.
Crossref
Crossref
Alexander Schnitzler, Andreas Gratz, Andre Bollacke, Michael Weyrich, Uwe Kuckländer, Bernhard Wünsch, Claudia Götz, Karsten Niefind & Joachim Jose. (2018) A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors. Pharmaceuticals 11:1, pages 23.
Crossref
Crossref
Robert Schulz, Amira Atef, Daniel Becker, Franziska Gottschalk, Carolin Tauber, Stefan Wagner, Christoph Arkona, Atef A. Abdel-Hafez, Hassan H. Farag, Jörg Rademann & Gerhard Wolber. (2018) Phenylthiomethyl Ketone-Based Fragments Show Selective and Irreversible Inhibition of Enteroviral 3C Proteases. Journal of Medicinal Chemistry 61:3, pages 1218-1230.
Crossref
Crossref
Samuel D Lotz & Alex Dickson. (2018) Unbiased Molecular Dynamics of 11 min Timescale Drug Unbinding Reveals Transition State Stabilizing Interactions. Journal of the American Chemical Society 140:2, pages 618-628.
Crossref
Crossref
Peter J. Tonge. (2017) Drug–Target Kinetics in Drug Discovery. ACS Chemical Neuroscience 9:1, pages 29-39.
Crossref
Crossref
Rachelle Prantil-BaunRichard NovakDebarun Das, Mahadevabharath R. Somayaji, Andrzej Przekwas & Donald E. Ingber. (2018) Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips. Annual Review of Pharmacology and Toxicology 58:1, pages 37-64.
Crossref
Crossref
Georges Vauquelin. (2018)
Link between a high
k
on
for drug binding and a fast clinical action: to be or not to be?
. MedChemComm 9:9, pages 1426-1438.
Crossref
Crossref
Larissa Catharina, Marcio Argollo de Menezes & Nicolas Carels. 2018. Theoretical and Applied Aspects of Systems Biology. Theoretical and Applied Aspects of Systems Biology
221
242
.
Georges Vauquelin. (2017)
Distinct
in vivo
target occupancy by bivalent- and induced-fit-like binding drugs
. British Journal of Pharmacology 174:23, pages 4233-4246.
Crossref
Crossref
Ilze Bot, Natalia V. Ortiz Zacarías, Wilhelmus E. A. de Witte, Henk de Vries, Peter J. van Santbrink, Daniël van der Velden, Mara J. Kröner, Dirk-Jan van der Berg, Dean Stamos, Elizabeth C. M. de Lange, Johan Kuiper, Adriaan P. IJzerman & Laura H. Heitman. (2017) A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy. Scientific Reports 7:1.
Crossref
Crossref
Ying Wang, Rohinton P. Edalji, Sanjay C. Panchal, Chaohong Sun, Stevan W. Djuric & Anil Vasudevan. (2017) Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program. Journal of Medicinal Chemistry 60:20, pages 8321-8335.
Crossref
Crossref
Fabian Paul, Christoph Wehmeyer, Esam T. Abualrous, Hao Wu, Michael D. Crabtree, Johannes Schöneberg, Jane Clarke, Christian Freund, Thomas R. Weikl & Frank Noé. (2017) Protein-peptide association kinetics beyond the seconds timescale from atomistic simulations. Nature Communications 8:1.
Crossref
Crossref
Andrea Martella, Huub Sijben, Arne C. Rufer, Uwe Grether, Juergen Fingerle, Christoph Ullmer, Thomas Hartung, Adriaan P. IJzerman, Mario van der Stelt & Laura H. Heitman. (2017)
A Novel Selective Inverse Agonist of the CB
2
Receptor as a Radiolabeled Tool Compound for Kinetic Binding Studies
. Molecular Pharmacology 92:4, pages 389-400.
Crossref
Crossref
Stephane De Cesco, Jerry Kurian, Caroline Dufresne, Anthony K. Mittermaier & Nicolas Moitessier. (2017) Covalent inhibitors design and discovery. European Journal of Medicinal Chemistry 138, pages 96-114.
Crossref
Crossref
Donald Huddler. 2017. Applied Biophysics for Drug Discovery. Applied Biophysics for Drug Discovery
1
5
.
Andrea Strasser, Hans-Joachim Wittmann & Roland Seifert. (2017) Binding Kinetics and Pathways of Ligands to GPCRs. Trends in Pharmacological Sciences 38:8, pages 717-732.
Crossref
Crossref
Katrin Kestav, Kaido Viht, Anton Konovalov, Erki Enkvist, Asko Uri & Darja Lavogina. (2017) Slowly on, Slowly off: Bisubstrate-Analogue Conjugates of 5-Iodotubercidin and Histone H3 Peptide Targeting Protein Kinase Haspin. ChemBioChem 18:8, pages 790-798.
Crossref
Crossref
Yu-ming M. Huang, Mark Anthony V. Raymundo, Wei Chen & Chia-en A. Chang. (2017) Mechanism of the Association Pathways for a Pair of Fast and Slow Binding Ligands of HIV-1 Protease. Biochemistry 56:9, pages 1311-1323.
Crossref
Crossref
Dong Guo, Laura H. Heitman & Adriaan P. IJzerman. (2016) Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors. Chemical Reviews 117:1, pages 38-66.
Crossref
Crossref
M. Bernetti, A. Cavalli & L. Mollica. (2017) Protein–ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling. MedChemComm 8:3, pages 534-550.
Crossref
Crossref
Ben J. Davis & Stephen D. Roughley. 2017. Platform Technologies in Drug Discovery and Validation. Platform Technologies in Drug Discovery and Validation
371
439
.
Timothy D. Owens & Yan Lou. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
76
103
.
G. Saladino, C. Estarellas & F.L. Gervasio. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
34
50
.
Timothy B. Durham & Michael R. Wiley. 2017. Translating Molecules into Medicines. Translating Molecules into Medicines
41
80
.
Robert A Copeland. (2016) Drug–target interaction kinetics: underutilized in drug optimization?. Future Medicinal Chemistry 8:18, pages 2173-2175.
Crossref
Crossref
Liliana M. Moreno-Vargas & Diego Prada-Gracia. (2016) New perspectives on the computational characterization of the kinetics of binding-unbinding in drug design: implications for novel therapies. Boletín Médico del Hospital Infantil de México 73:6, pages 424-431.
Crossref
Crossref
Wilhelmus E.A. de Witte, Meindert Danhof, Piet H. van der Graaf & Elizabeth C.M. de Lange. (2016) In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant. Trends in Pharmacological Sciences 37:10, pages 831-842.
Crossref
Crossref
Alexander Heifetz, Tim James, Inaki Morao, Michael J Bodkin & Philip C. Biggin. (2016) Guiding lead optimization with GPCR structure modeling and molecular dynamics. Current Opinion in Pharmacology 30, pages 14-21.
Crossref
Crossref
Georges Vauquelin. (2016)
Cell membranes… and how long drugs may exert beneficial pharmacological activity
in vivo
. British Journal of Clinical Pharmacology 82:3, pages 673-682.
Crossref
Crossref
Georges Vauquelin. (2016)
Effects of target binding kinetics on
in vivo
drug efficacy: k
off
, k
on
and rebinding
. British Journal of Pharmacology 173:15, pages 2319-2334.
Crossref
Crossref
Leonid T. Cherney & Sergey N. Krylov. (2016) Slow-Equilibration Approximation in Kinetic Size Exclusion Chromatography. Analytical Chemistry 88:7, pages 4063-4070.
Crossref
Crossref
Georges Vauquelin, Isabelle Van Liefde & David C Swinney. (2016) On the different experimental manifestations of two-state ‘induced-fit’ binding of drugs to their cellular targets. British Journal of Pharmacology 173:8, pages 1268-1285.
Crossref
Crossref
Patrick Masson & Sofya V. Lushchekina. (2016) Slow-binding inhibition of cholinesterases, pharmacological and toxicological relevance. Archives of Biochemistry and Biophysics 593, pages 60-68.
Crossref
Crossref
Charu Chaudhry, Jonathan Davis, Yong Zhang, Shana Posy, Ming Lei, Henry Shen, Chunhong Yan, Brigitte Devaux, Litao Zhang, Yuval Blat, William Metzler, Robert M. Borzilleri & Randy L. Talbott. (2016) Building homogeneous time-resolved fluorescence resonance energy transfer assays for characterization of bivalent inhibitors of an inhibitor of apoptosis protein target. Analytical Biochemistry 497, pages 8-17.
Crossref
Crossref
Robert A. Copeland. (2015) The drug–target residence time model: a 10-year retrospective. Nature Reviews Drug Discovery 15:2, pages 87-95.
Crossref
Crossref
Karim M. ElSawy, David P. Lane, Chandra S. Verma & Leo S. D. Caves. (2016) Recognition Dynamics of p53 and MDM2: Implications for Peptide Design. The Journal of Physical Chemistry B 120:2, pages 320-328.
Crossref
Crossref
Vadim Bernard-Gauthier, Justin Bailey, Sheldon Berke & Ralf Schirrmacher. (2015) Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. Molecules 20:12, pages 22000-22027.
Crossref
Crossref
Tjerk Bueters, Christopher Gibson & Sandra A G Visser. (2015) Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. Future Medicinal Chemistry 7:17, pages 2351-2369.
Crossref
Crossref
Georges Vauquelin, Isabelle Van Liefde & David C. Swinney. (2015) Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context. Drug Discovery Today: Technologies 17, pages 28-34.
Crossref
Crossref
Andreas Schoop & Fabian Dey. (2015) On-rate based optimization of structure–kinetic relationship – surfing the kinetic map. Drug Discovery Today: Technologies 17, pages 9-15.
Crossref
Crossref
Dennis J. Murphy, Yangsi Ou, Danielle H. Euler, Keith Wessner, Sharon Adamski, Bin Luo, Gregg A. Wesolowski, Robert Vogel, Helmut Glantschnig, Laura S. Lubbers, Stephen S. Carroll & Ming-Tain Lai. (2015) Determination of in Vivo Enzyme Occupancy Utilizing Inhibitor Dissociation Kinetics. Journal of the American Chemical Society 137:35, pages 11230-11233.
Crossref
Crossref
Julien Louvel, Dong Guo, Marjolein Soethoudt, Tamara A.M. Mocking, Eelke B. Lenselink, Thea Mulder-Krieger, Laura H. Heitman & Adriaan P. IJzerman. (2015) Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists. European Journal of Medicinal Chemistry 101, pages 681-691.
Crossref
Crossref
J Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, Angelina Bisconte, Danny Tam, Vernon T Phan, Sergei Romanov, David Finkle, Jin Shu, Vaishali Patel, Tony Ton, Xiaoyan Li, David G Loughhead, Philip A Nunn, Dane E Karr, Mary E Gerritsen, Jens Oliver Funk, Timothy D Owens, Erik Verner, Ken A Brameld, Ronald J Hill, David M Goldstein & Jack Taunton. (2015) Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nature Chemical Biology 11:7, pages 525-531.
Crossref
Crossref
Grant K Walkup, Zhiping You, Philip L Ross, Eleanor K H Allen, Fereidoon Daryaee, Michael R Hale, John O'Donnell, David E Ehmann, Virna J A Schuck, Ed T Buurman, Allison L Choy, Laurel Hajec, Kerry Murphy-Benenato, Valerie Marone, Sara A Patey, Lena A Grosser, Michele Johnstone, Stephen G Walker, Peter J Tonge & Stewart L Fisher. (2015) Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nature Chemical Biology 11:6, pages 416-423.
Crossref
Crossref
Rumin Zhang. (2015) Which trails are your drugs taking?. Nature Chemical Biology 11:6, pages 382-383.
Crossref
Crossref
John A. ChristopherSarah J. AvesJason BrownJames C. ErreySuki S. KlairChristopher J. Langmead, Oliver J. MaceRichard MouldJayesh C. PatelBenjamin G. TehanAndrei ZhukovFiona H. MarshallMiles Congreve. (2015) Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm 6:5, pages 947-955.
Crossref
Crossref
Robert A. Copeland. 2015. Thermodynamics and Kinetics of Drug Binding. Thermodynamics and Kinetics of Drug Binding
155
167
.
Andrew Chang, Kanishk Kapilashrami, Eleanor K. H. Allen & Peter J. Tonge. 2015. Thermodynamics and Kinetics of Drug Binding. Thermodynamics and Kinetics of Drug Binding
295
311
.
Dong Guo, Adriaan P. IJzerman & Laura H. Heitman. 2015. Thermodynamics and Kinetics of Drug Binding. Thermodynamics and Kinetics of Drug Binding
257
272
.
Felix Schiele, Pelin Ayaz & Anke Müller‐Fahrnow. 2015. Thermodynamics and Kinetics of Drug Binding. Thermodynamics and Kinetics of Drug Binding
237
256
.
Weiqiang Xing, Jing Ai, Shiyu Jin, Zhangxing Shi, Xia Peng, Lang Wang, Yinchun Ji, Dong Lu, Yang Liu, Meiyu Geng & Youhong Hu. (2015) Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. European Journal of Medicinal Chemistry 95, pages 302-312.
Crossref
Crossref
Mathias Hallberg. (2015) Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors. Medicinal Research Reviews 35:3, pages 464-519.
Crossref
Crossref
Z Yu, A P IJzerman & L H Heitman. (2015)
K
v
11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical K
v
11.1 (hERG) inhibitors
. British Journal of Pharmacology 172:3, pages 940-955.
Crossref
Crossref
Gerhard Klebe. (2015) The Use of Thermodynamic and Kinetic Data in Drug Discovery: Decisive Insight or Increasing the Puzzlement?. ChemMedChem 10:2, pages 229-231.
Crossref
Crossref
Ruth Nussinov & Chung-Jung Tsai. (2015) The Design of Covalent Allosteric Drugs. Annual Review of Pharmacology and Toxicology 55:1, pages 249-267.
Crossref
Crossref
Carlos H. Ríos Martínez, Laura Lagartera, Cristina Trujillo & Christophe Dardonville. (2015) Bisimidazoline arylamides binding to the DNA minor groove: N1-hydroxylation enhances binding affinity and selectivity to AATT sites. MedChemComm 6:11, pages 2036-2042.
Crossref
Crossref
Jiayin Bao, Svetlana M. Krylova, Leonid T. Cherney, J. C. Yves Le Blanc, Patrick Pribil, Philip E. Johnson, Derek J. Wilson & Sergey N. Krylov. (2015) Pre-equilibration kinetic size-exclusion chromatography with mass spectrometry detection (peKSEC-MS) for label-free solution-based kinetic analysis of protein?small molecule interactions. The Analyst 140:4, pages 990-994.
Crossref
Crossref
Karen L. Rigat, Hao Lu, Ying-Kai Wang, Argyrides Argyrou, Caroline Fanslau, Brett Beno, Yi Wang, Jovita Marcinkeviciene, Min Ding, Robert G. Gentles, Min Gao, Lynn M. Abell & Susan B. Roberts. (2014) Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase. Journal of Biological Chemistry 289:48, pages 33456-33468.
Crossref
Crossref
Juan Antonio Alonso, Miriam Andrés, Mónica Bravo, Maria Antonia Buil, Marta Calbet, Jordi Castro, Paul R. Eastwood, Peter Eichhorn, Cristina Esteve, Elena Gómez, Jacob González, Marta Mir, Silvia Petit, Richard S. Roberts, Bernat Vidal, Laura Vidal, Pere Vilaseca & Miriam Zanuy. (2014) Structure–activity relationships (SAR) and structure–kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I. Bioorganic & Medicinal Chemistry Letters 24:21, pages 5118-5122.
Crossref
Crossref
Juan Antonio Alonso, Miriam Andrés, Mónica Bravo, Marta Calbet, Paul R. Eastwood, Peter Eichhorn, Cristina Esteve, Manel Ferrer, Elena Gómez, Jacob González, Marta Mir, Imma Moreno, Silvia Petit, Richard S. Roberts, Sara Sevilla, Bernat Vidal, Laura Vidal, Pere Vilaseca & Miriam Zanuy. (2014) Structure–activity relationships (SAR) and structure–kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists II: Lead optimization. Bioorganic & Medicinal Chemistry Letters 24:21, pages 5123-5126.
Crossref
Crossref
Juan Antonio Alonso, Miriam Andrés, Mónica Bravo, Maria Antonia Buil, Marta Calbet, Jordi Castro, Paul R. Eastwood, Cristina Esteve, Manel Ferrer, Pilar Forns, Elena Gómez, Jacob González, Estrella Lozoya, Marta Mir, Imma Moreno, Silvia Petit, Richard S. Roberts, Sara Sevilla, Bernat Vidal, Laura Vidal & Pere Vilaseca. (2014) Structure–activity relationships (SAR) and structure–kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists III: The role of a hydrogen-bond acceptor in long receptor residence times. Bioorganic & Medicinal Chemistry Letters 24:21, pages 5127-5133.
Crossref
Crossref
Jiayin Bao, Svetlana M. Krylova, Leonid T. Cherney, J. C. Yves LeBlanc, Patrick Pribil, Philip E. Johnson, Derek J. Wilson & Sergey N. Krylov. (2014) Kinetic Size-Exclusion Chromatography with Mass Spectrometry Detection: An Approach for Solution-Based Label-Free Kinetic Analysis of Protein–Small Molecule Interactions. Analytical Chemistry 86:20, pages 10016-10020.
Crossref
Crossref
Kwok-Wing Yiu, Chi-Kin Lee, Ka-Cheung Kwok & Nai-Ho Cheung. (2014) Measuring the Kinetics of the Binding of Xenoestrogens and Estrogen Receptor Alpha by Fluorescence Polarization. Environmental Science & Technology 48:19, pages 11591-11599.
Crossref
Crossref
Georges Vauquelin, Giampiero Bricca & Isabelle Van Liefde. (2014) Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands. Fundamental & Clinical Pharmacology 28:5, pages 530-543.
Crossref
Crossref
David C Swinney, Paul Beavis, Kai-Ting Chuang, Yue Zheng, Ina Lee, Peter Gee, Jerome Deval, David M Rotstein, Marianna Dioszegi, Palani Ravendran, Jun Zhang, Surya Sankuratri, Rama Kondru & Georges Vauquelin. (2014) A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. British Journal of Pharmacology 171:14, pages 3364-3375.
Crossref
Crossref
Julien Louvel, Dong Guo, Marta Agliardi, Tamara A. M. Mocking, Roland Kars, Tan Phát Pham, Lizi Xia, Henk de Vries, Johannes Brussee, Laura H. Heitman & Adriaan P. IJzerman. (2014)
Agonists for the Adenosine A
1
Receptor with Tunable Residence Time. A Case for Nonribose 4-Amino-6-aryl-5-cyano-2-thiopyrimidines
. Journal of Medicinal Chemistry 57:8, pages 3213-3222.
Crossref
Crossref
Pan Pan, Susan E. Knudson, Gopal R. Bommineni, Huei-Jiun Li, Cheng-Tsung Lai, Nina Liu, Miguel Garcia-Diaz, Carlos Simmerling, Sachindra S. Patil, Richard A. Slayden & Peter J. Tonge. (2014) Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy. ChemMedChem 9:4, pages 776-791.
Crossref
Crossref
T Sakurai, K Ogawa, Y Ishihara, S Kasai & M Nakayama. (2014)
The
MCH
1
receptor, an anti‐obesity target, is allosterically inhibited by 8‐methylquinoline derivatives possessing subnanomolar binding and long residence times
. British Journal of Pharmacology 171:5, pages 1287-1298.
Crossref
Crossref
Mirzo Kanoatov, Leonid T. Cherney & Sergey N. Krylov. (2014) Extracting Kinetics from Affinity Capillary Electrophoresis (ACE) Data: A New Blade for the Old Tool. Analytical Chemistry 86:2, pages 1298-1305.
Crossref
Crossref
Georges Vauquelin. (2013) Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time. Naunyn-Schmiedeberg's Archives of Pharmacology 386:11, pages 949-962.
Crossref
Crossref
Alan M. Palmer & Mohammad S. Alavijeh. (2018) Overview of Experimental Models of the Blood‐Brain Barrier in CNS Drug Discovery. Current Protocols in Pharmacology 62:1.
Crossref
Crossref
Rudi Agius, Mieczyslaw Torchala, Iain H. Moal, Juan Fernández-Recio & Paul A. Bates. (2013) Characterizing Changes in the Rate of Protein-Protein Dissociation upon Interface Mutation Using Hotspot Energy and Organization. PLoS Computational Biology 9:9, pages e1003216.
Crossref
Crossref
Göran Dahl & Tomas Akerud. (2013) Pharmacokinetics and the drug–target residence time concept. Drug Discovery Today 18:15-16, pages 697-707.
Crossref
Crossref
Andrea BortolatoBen G. TehanMichael S. BodnarchukJonathan W. EssexJonathan S. Mason. (2013)
Water Network Perturbation in Ligand Binding: Adenosine A
2A
Antagonists as a Case Study
. Journal of Chemical Information and Modeling 53:7, pages 1700-1713.
Crossref
Crossref
Fang BaiYechun XuJing ChenQiufeng LiuJunfeng Gu, Xicheng Wang, Jianpeng Ma, Honglin Li, José N. OnuchicHualiang Jiang. (2013) Free energy landscape for the binding process of Huperzine A to acetylcholinesterase. Proceedings of the National Academy of Sciences 110:11, pages 4273-4278.
Crossref
Crossref
Robert A. Copeland. 2013. Evaluation of Enzyme Inhibitors in Drug Discovery. Evaluation of Enzyme Inhibitors in Drug Discovery
287
344
.
Ye Fang. (2013) Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. Journal of Pharmacological and Toxicological Methods 67:2, pages 69-81.
Crossref
Crossref
Nayana Kamtekar, Anita Pandey, Neeraj Agrawal, Raghuvir R. S. Pissurlenkar, Mohanish Borana & Basir Ahmad. (2013) Interaction of Multimicrobial Synthetic Inhibitor 1,2-Bis(2-Benzimidazolyl)-1,2-Ethanediol with Serum Albumin: Spectroscopic and Computational Studies. PLoS ONE 8:1, pages e53499.
Crossref
Crossref
Mengzhu Xue, Shoude Zhang, Chaoqian Cai, Xiaojuan Yu, Lei Shan, Xiaofeng Liu, Weidong Zhang & Honglin Li. (2013) Predicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-11.
Crossref
Crossref
Rumin Zhang & William T. Windsor. 2013. Antiviral Methods and Protocols. Antiviral Methods and Protocols
59
79
.
Huayun Deng, Chaoming Wang, Ming Su & Ye Fang. (2012) Probing Biochemical Mechanisms of Action of Muscarinic M3 Receptor Antagonists with Label-Free Whole Cell Assays. Analytical Chemistry 84:19, pages 8232-8239.
Crossref
Crossref
David E. Ehmann, Haris Jahić, Philip L. Ross, Rong-Fang Gu, Jun Hu, Gunther Kern, Grant K. Walkup & Stewart L. Fisher. (2012) Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor. Proceedings of the National Academy of Sciences 109:29, pages 11663-11668.
Crossref
Crossref
Georges Vauquelin, Sophie Bostoen, Patrick Vanderheyden & Philip Seeman. (2012) Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn-Schmiedeberg's Archives of Pharmacology 385:4, pages 337-372.
Crossref
Crossref
Karim M. ElSawy, Reidun Twarock, David P. Lane, Chandra S. Verma & Leo S. D. Caves. (2011) Characterization of the Ligand Receptor Encounter Complex and Its Potential for in Silico Kinetics-Based Drug Development. Journal of Chemical Theory and Computation 8:1, pages 314-321.
Crossref
Crossref
Hanna Andersson & Mathias Hallberg. (2012) Discovery of Inhibitors of Insulin-Regulated Aminopeptidase as Cognitive Enhancers. International Journal of Hypertension 2012, pages 1-18.
Crossref
Crossref
Georges Vauquelin. (2012) Determination of drug–receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance. MedChemComm 3:6, pages 645.
Crossref
Crossref
Geoffrey A. Holdgate & Adrian L. Gill. (2011) Kinetic efficiency: the missing metric for enhancing compound quality?. Drug Discovery Today 16:21-22, pages 910-913.
Crossref
Crossref
Jos H.M. Lange, Jennifer Venhorst, Maria J.P. van Dongen, Jurjen Frankena, Firas Bassissi, Natasja M.W.J. de Bruin, Cathaline den Besten, Stephanie B.A. de Beer, Chris Oostenbrink, Natalia Markova & Chris G. Kruse. (2011) Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors. European Journal of Medicinal Chemistry 46:10, pages 4808-4819.
Crossref
Crossref
Tino Rossi & Simone Braggio. (2011) Quality by Design in lead optimization: a new strategy to address productivity in drug discovery. Current Opinion in Pharmacology 11:5, pages 515-520.
Crossref
Crossref
Tim Luker, Lilian Alcaraz, Kamaldeep K. Chohan, Niklas Blomberg, Dearg S. Brown, Roger J. Butlin, Thomas Elebring, Andrew M. Griffin, Simon Guile, Stephen St-Gallay, Britt-Marie Swahn, Steve Swallow, Michael J. Waring, Mark C. Wenlock & Paul D. Leeson. (2011) Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. Bioorganic & Medicinal Chemistry Letters 21:19, pages 5673-5679.
Crossref
Crossref
Robert A Copeland. (2011) Conformational adaptation in drug–target interactions and residence time. Future Medicinal Chemistry 3:12, pages 1491-1501.
Crossref
Crossref
Robert A. Copeland, Aravind Basavapathruni, Mikel Moyer & Margaret Porter Scott. (2011) Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Analytical Biochemistry 416:2, pages 206-210.
Crossref
Crossref
Simon J. Teague. (2011) Learning lessons from drugs that have recently entered the market. Drug Discovery Today 16:9-10, pages 398-411.
Crossref
Crossref